News
The ASAM Weekly for August 18, 2026
We open this week with virtual care. One of the few silver linings of the public health emergency was the rapid expansion of telehealth—a shift from which our patients in SUD treatment settings stand to benefit immensely. An exploratory analysis of the rollout of a virtual SUD clinic across Texas offers key insights on implementing MOUD via telehealth effectively. Next, an RCT shared ties in culturally grounded interventions for Urban American Indian and Alaska Native populations, addressing a historically underserved community in our field. Shifting from digital care to digital harms, a major headline this week highlights ongoing social media litigation, begging the question: just how addictive are these platforms?
We then turn to aging on multiple fronts. First, a study on epigenetic age acceleration reinforces the link between substance use—specifically cigarette smoking and opioid use—and accelerated biological aging. Turning to addiction in later life, alcohol use patterns are examined in the Australia “Beyond 50” cohort, while a systematic review on gambling in older adults helps identify key risk factors in this understudied demographic.
To continue in the area of diagnosis, a new ICD code provides much-needed clarity on the rising prevalence of cannabis hyperemesis syndrome (a topic also spotlighted by Forbes in a physician explainer this week). To help clinicians reduce missed diagnoses of opioid use disorder, the SCOPE framework is introduced as a tool to identify OUD using both individual risk factors and social determinants of health. Finally, a KFF News piece highlights how federal policy can inadvertently hinder clinical practice by restricting access to harm-reduction test strips needed to identify what substances our patients are using.
While virtual care and digital innovation opened this week’s issue, we turn to our foundation in basic science to close. A study in Translational Psychiatry examines the neurobiological effects of alcohol exposure on behavioral resilience in a rodent model, reminding us that behind every digital tool, policy debate, and diagnostic code lies the complex brain circuitry driving addiction. Whether you work in basic science, clinical practice, or policy, thank you for all you do.
Smita Das, MD, PhD, MPH
Editor in Chief
with Co-Editors: Brandon Aden, MD, MPH, FASAM; John A. Fromson, MD; Sarah Messmer, MD, FASAM; Jack Woodside, MD; and Contributing Editor: Jessica Gregg, MD, PhD, FASAM
ASAM is seeking up to 3 members to serve on the Publications Council beginning in January 2027. Council members should have experience in addiction medicine and familiarity with the writing and publishing process. The Publications Council is charged with overseeing ASAM publications. The Council approves publication editors, evaluates proposals for new publications, ensures adequate publisher performance, and regularly furnishes the Board of Directors with updates on publication activities.
Please first log into your ASAM member portal and click to apply.
The closing date is September 21, 2026.
This exploratory case study identifies barriers, facilitators, and implementation needs during the phases of implementation of a virtual SUD clinic offering low-barrier medications for opioid use disorder (MOUD) across the state of Texas. From January 2022 to September 2023, researchers conducted 10 individual and 11 group periodic reflections with 16 individuals (including clinic leadership, operation staff, and providers) to evaluate implementation activities, clinic processes, and events during the rollout of the virtual clinic. In the preparation phase, participants emphasized the importance of strong leadership, effective workforce and technology infrastructure, staff training, and mission alignment. During implementation, participants highlighted the need for strong interprofessional communication, continuous reflection and evaluation, and medication supply chain management, as well as the challenge of workforce turnover. In the sustainment phase, participants identified a need for diversified funding and intentional growth.
The National Institute on Drug Abuse (NIDA) has issued a Request for Information (RFI) inviting feedback on the 2027–2031 NIDA Strategic Plan.
To view the RFI and submit feedback, please see:
NOT-DA-26-014: Request for Information: Inviting Input on NIDA’s Strategic Plan for 2027–2031
To ensure consideration, responses must be submitted by:
September 21, 2026, 11:59:59 PM EST
Chronic alcohol use and acute stress disrupt emotion regulation and behavioral inhibition, but individual variability suggests underlying mechanisms of vulnerability and resilience. Using a conditioned inhibition paradigm, researchers assessed Long Evans rats with prior alcohol exposure and/or stress on fear and reward cue discrimination alongside corticolimbic interneuron markers. While all animals eventually learned cue distinctions, females with combined alcohol and stress exposure showed impaired suppression of fear when inhibitory cues were present. Behavioral resilience or vulnerability corresponded to distinct patterns of parvalbumin- and protein kinase C-δ (PKCδ)-expressing interneuron network organization, highlighting sex-specific effects and neural correlates of inhibitory control.
Gambling in older adults represents an emerging but still under-recognized mental health concern. A systematic review of studies involving adults aged ≥55 years with gambling were identified. Commonly identified correlates to gambling-related problems included loneliness, reduced social support, financial difficulties, male gender, stressful life events, and early gambling initiation. Gambling was frequently reported as a recreational activity, but could become maladaptive when used as a strategy to regulate negative emotions or cope with social isolation. Psychiatric comorbidity, particularly depression and anxiety, was frequently observed in clinical and high-risk samples. Evidence regarding psychological interventions remains limited but suggests potential benefits.
DNA methylation (DNAm) increases with age as well as with various environmental and psychosocial exposures, such as tobacco, social stress, chronic inflammation, and toxins. Various epigenetic clocks have been developed that use DNAm at genomic sites to estimate epigenetic age acceleration (EAA). This study used individuals’ (n=2276) data from a health interview conducted in Indiana with saliva analyzed for DNAm. The 11% that were assessed to be intermediate to high risk for SUD had EAA 21% faster than chronological age. The 20% who smoked daily had EAA 10% faster than chronological age. Vaping alone had no significant EAA. Illicit opioid use had EAA 3.6% faster, however the effect was reduced by about half when controlled for the effects of smoking. The researchers conclude that substance use is associated with accelerated biological aging and call for research on the mechanisms.
Researchers conducted a longitudinal cohort study evaluating healthy aging, particularly examining substance use among those 50–70 years of age in Australia. Researchers found significant rates of substance use, with 85.2% reporting current alcohol use and 52.4% screening positive for possible problematic alcohol use. In addition, 3.7% reported current cannabis use, 8.7% reporting tobacco use, and 5.5% reported other current non-medical substance use (3.7% sedatives, 0.9% stimulants, and 0.9% other psychoactive substances). Researchers also found that 12.7% had moderate or severe anxiety and 16.4% had moderate or severe depression. These findings demonstrate vulnerabilities in this population and the necessity for clinicians to identify and address substance use, particularly alcohol use, in an aging population.
This resource guide compares the three formulations of extended-release, long-acting treatments for substance use disorder. It highlights differences in dosing, administration, and proper injection technique.
Download Resource hereThis randomized clinical trial tested two culturally grounded virtual interventions for substance use among urban American Indian and Alaska Native emerging adults (n=541, ages 18 to 25). Participants were recruited from December 2020 to October 2023 across the US and were randomized to receive either Three Traditions and Connections for Urban Native Americans (TACUNA) workshops and a wellness circle or an opioid education health and wellness cultural (HWC) workshop (usual care). Participants completed 3-, 6-, and 12-month surveys. The primary outcome was opioid, alcohol, and cannabis use, with secondary outcomes focused on consequences of substance use, mental health, cultural connection, and peer influence.
Both arms reported decreased frequency of cannabis use, decreased rates of positive screens for AUD and CUD, and improvement in rates of clinical depression and anxiety as well as time spent with peers using substances. Only TACUNA participants reported decreases in frequency and quantity of alcohol use and quantity of cannabis use.
On October 1, 2025, ICD-10-CM introduced a diagnosis code specific for cannabis hyperemesis syndrome (R11.16). Prior, cannabis hyperemesis syndrome (CHS) was indicated by a diagnosis for emesis (R11) combined with a cannabis related diagnosis. This report examined data from the CDC’s National Syndromic Surveillance Program. From January 2023 to September 2025, CHS ED visits made up 3.19 ED visits/100,000 ED visits. During October 2025 to May 2026 (after introduction of the new ICD code), CHS ED visits made up 11.97 ED visits/100,000 ED visits, 3.7 times the previous rate. CHS was most prevalent in people aged 15–24 yrs 38.7 ED visits/100,000. The authors believe the CHS rate after the introduction of the new code is a more accurate estimate of the true impact and that CHS deserves increased awareness among clinicians and the public.
Tools used to screen for opioid use disorder (OUD) are limited, particularly due to concerns about generalizability. Researchers using data from the All of Us Research Program with >600,000 participants developed the Social and Clinical Opioid Use Disorder Predisposition Evaluation (SCOPE) risk calculator. Researchers examined 69 potential social determinants of health, demographic and clinical features, and identified 8 predictors, including history of depression, employment, housing stability, and others, as significant predictors. The SCOPE model had a sensitivity of 78% and specificity of 78%. Given that the model is only eight questions, the researchers argue that it could be useful in clinical decision-making.
- Is social media addiction real? Law and science collide in blockbuster federal suit 🔓Los Angeles Times
- These doctors perform daily miracles, no hospital in sightThe New York Times
- Grief, addiction and a dizzying carousel: An opera tackles the opioid crisisThe New York Times
- What happens to the body with regular cannabis use? A doctor explainsForbes
- A federal policy is complicating how organizations battle the opioid crisis 🔓WYPR / KFF Health News
- Another social media ‘addiction’ trial starts today. Its claims are weak—but dangerous 🔓Reason
- Trump administration’s new ‘treatment first’ addiction toolkit emphasizes faith, abstinenceSTAT
- Addiction experts on Brad Pitt: “Alcoholics are a horrible source of information about themselves” 🔓The Hollywood Reporter